Latest Breaking News On - Orldwide licensing agreement - Page 1 : comparemela.com

– Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of I ND-enabling studies with IND filing.

United statesGiiant pharmaChristophe mellonJenene thomasCompany annual report on formPalisade bio incCompany quarterly report on formColitis foundationExchange commissionGiiant pharma incChief executive officerPalisade bioChief executivePrecision deliveryPrivate securities litigation reform actAnnual report